Three-year deal with Guava adds micro-cytometry instruments, reagents and analysis software to portfolio of cellular analysis solutions available in Japan
Amersham Biosciences has signed an exclusive three-year distribution agreement covering the territory of Japan with Guava Technologies for Guava personal cell analysis (PCA) systems, reagents and software modules.
By adding the Guava PCA systems to its portfolio, Amersham Biosciences now offers micro-cytometry instruments, reagents and analysis software.
Guava's products have broad applications in scientific research, drug discovery, cell counting, and optimisation of commercial bioproduction.
The Guava PCA systems offer an integrated, optimised approach that takes the guesswork out of single cell analysis and counting.
Based on patented micro-capillary technology, the Guava PCA systems are available in three configurations.
With flexible and ultra-compact systems, cell analysis with the Guava PCA requires only a few microlitres of sample volume.
This results in substantial savings in precious and expensive cells, reagents and compounds.
Guava offers a range of assays and dedicated software modules enhancing the Guava PCA system's overall ease-of-use.
The Guava PCA systems are complementary to Amersham Biosciences's cellular analysis reagents and In Cell analyser platforms to provide a comprehensive cellular analysis offering, supported by Amersham Biosciences's distribution, marketing, sales and support franchise.
Compatibility of reagents from both companies across the In Cell analyser and PCA platforms will simplify and improve cellular analysis applications and extend a more complete systems offering to customers.
Keiko Hattori, president, Japan and International at Amersham Biosciences says: "We are delighted to have signed this distribution agreement with Guava Technologies.
"In the past, technology based instrumentation has created bottlenecks rather than removed them in all cell based research and cell health monitoring applications.
"The agreement means we can offer customers powerful instrumentation coupled with integrated software and optimised reagents, helping them improve the laboratories productivity and work flow". "We are very pleased and excited to be working with Amersham Biosciences" says Paul Kinnon vice president commercial development, Guava Technologies.
"Our experience in the decentralised cellular analysis market, coupled with the extensive marketing and commercial support of Amersham Biosciences, will strengthen our presence in the vibrant Japanese life sciences market and promote higher productivity in drug development and scientific research as it relates to cell analysis".
The Guava Technologies products now available from Amersham Biosciences include: The Guava PCA, PCA-96 and PCA-96 AFP (auto fluorescent protein) platforms with software modules and reagent kits including Guava ViaCount, Nexin, Express, MultiCaspase, Tunel, Cell Cycle software modules and the Express AFP software module for the PCA-96 AFP.
